; Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies

VIEWS: 154 PAGES: 209

Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies Summary GBI Research’s new report, “Early Stage Drug Development in Disease Segments – Innovation Focuses on Stem Cell Therapies and Gene Therapies”, provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research finds that early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development. The majority of the molecules in the early stages of development are being developed f

More Info
  • pg 1
									            Early Stage Drug Discovery in Disease Segments -
          Innovation Focuses on Stem Cell Therapies and Gene
                                Therapies
 Reference Code: GBIHC076MR                                                                                                                                                                                                                                                                                                                           Publication Date: February 2011


                                     Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline
    Early stage drug                 Early stage drug discovery includes drugs under development in the discovery and preclinical
    development includes             stages of development. These studies are conducted in order to assess the safety and efficacy of
    drugs under development          the drug. This stage of development plays a key role in drug development as it determines potential
    in the discovery and             molecules to be further processed for development by different companies. Increased strategies
    preclinical stages of            like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are
    development.                     persuading companies to implement safety scrutiny measures at early stages of discovery.
                                     The majority of the molecules in the early stages of discovery are being developed for cancer
                                     indications. Molecules under development for breast cancer account for 23% of the total early
                                     stage development molecules under development for cancer. This is followed by prostate cancer,
                                     accounting for 20%, followed by colon cancer (15%).
                                     Other than Oncology, other therapeutic areas with high activity in Research and Development
                                     (R&D) in early development phases include Central Nervous System (CNS) disorders,
                                     immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage
                                     drugs under development, followed by immunological disorders (13%) and metabolic disorders
                                     (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders
                                     (9%) and infectious disease (9%) segments.

                                      Early Stage Drug Discovery in Disease Segments, Early Stage R&D pipeline in Different
                                      Therapeutic Segments, December 2010

                                                              160

                                                              140

                                                              120
                                        Number of Molecules




                                                              100

                                                               80

                                                               60

                                                               40

                                                               20

                                                                0
                                                                                                                                                                                                                                                                                                                                                                Ovarian Cancer
                                                                    Schizophrenia

                                                                                    Parkinson's Disease



                                                                                                                               Alzheimer's Disease

                                                                                                                                                     Diabetes

                                                                                                                                                                Obesity
                                                                                                          Multiple Sclerosis




                                                                                                                                                                          Hepatitis



                                                                                                                                                                                                     Myocardial Infarction

                                                                                                                                                                                                                             PAH

                                                                                                                                                                                                                                   Atherosclerosis

                                                                                                                                                                                                                                                     Dyslipidemia




                                                                                                                                                                                                                                                                                                     Crohn's Disease



                                                                                                                                                                                                                                                                                                                                                      Allergy




                                                                                                                                                                                                                                                                                                                                                                                        Prostate Cancer

                                                                                                                                                                                                                                                                                                                                                                                                          Lung Cancer

                                                                                                                                                                                                                                                                                                                                                                                                                        Melanoma

                                                                                                                                                                                                                                                                                                                                                                                                                                   Breast Cancer

                                                                                                                                                                                                                                                                                                                                                                                                                                                   Colon Cancer
                                                                                                                                                                                                                                                                    HIV/AIDS

                                                                                                                                                                                                                                                                               Rheumatoid Arhritis




                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Bladder Cancer
                                                                                                                                                                                                                                                                                                                       Systemic Lupus Erythematosus




                                                                                                                                                                                                                                                                                                                                                                                 NSLC
                                                                                                                                                                                      Hypertension




                                      Source: GBI Research, GBI Research Internal Database, Clinical Trials.gov, Company websites




Early Stage Drug Discovery in Disease Segments - Innovation                                                                                                                                                                                                                                                                                             GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Page 1
                                                                                                                                                                                          © GBI Research. This is a licensed product and is not to be photocopied
                                     Breast Cancer Therapeutics Leads the Early Stage Drug Discovery Pipeline; Immunotherapy
                                     accounts for 33% of the Drug Classes Under Development
                                     The breast cancer early stage pipeline consists of 141 molecules, with 22 molecules in the
The breast cancer early              discovery phase and 119 molecules in the preclinical phase. These molecules are in development
stage pipeline consists of           for the treatment of patients suffering with breast cancer. The discovery phase of the breast cancer
141 molecules, with 22               pipeline consists of 16% of the molecules and the preclinical phase consists of 84% of the pipeline.
molecules in the discovery
phase and 119 molecules               Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by
in the preclinical phase.             Mechanism of Action in Breast Cancer (%), December 2010

                                                                         13%

                                                                                       16%
                                                           2%                                                                                          1%
                                                                                                                                   1%
                                                      5%
                                                                                                                                                                 1%
                                                                                                3%


                                                                                                                                                                      1%
                                                                                                  8%
                                                                                                                        1%




                                                                                               8%
                                                     34%                                                                                                        1%
                                                                                                                                    1%

                                                                                  12%




                                           Vaccine                                Enzyme inhibitors                                Immunotherapy
                                           gene therapy                           combination therapy                              stem cell therapy
                                           hormones                               Miscellaneous                                    Protein receptor targetors
                                           Apoptosis targetors                    chemotherapy                                     angiogenic antagonist
                                           cellular motility inhibitor            synthetic picolinic ester-substituted retinoid   microtubule inhibitor


                                      Source: GBI Research, GBI Research Internal Database, ClinicalTrials.gov, Company websites




                                     The early stage breast cancer therapeutics pipeline has been supplemented by novel therapeutic
                                     molecules. Immunotherapy, with 47 molecules, contributes 33% of the pipeline. Protein receptor
                                     targetors contribute 16%. Enzyme inhibitors contribute 12% of the pipeline. Vaccines contribute 8%
                                     of the pipeline. Gene therapy contributes 5% of the pipeline. Apoptosis targetors contribute to 3%.
                                     Chemotherapy, angiogenic antagonists, stem cell therapy and hormones with two molecules each
                                     contribute 1%. Combination therapy, with three molecules, contributes 2%. Cellular motility
                                     inhibitors, synthetic picolinic ester-substituted retinoids, microtubule inhibitors with one molecule
                                     each contribute to 1% each. Few drugs with the mechanisms of action apart from these major
                                     classes contribute to 13% of the pipeline.




Early Stage Drug Discovery in Disease Segments - Innovation                                                                   GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                                                      Page 2
                                                                               © GBI Research. This is a licensed product and is not to be photocopied
                                     Key Players in the Early Stage Drug Discovery Pipeline are Hanall Pharmaceutical, Patrys
                                     and F. Hoffman La Roche
                                     In Early stage drug discovery, as in, drugs in the discovery and preclinical phases of development,
                                     the key players were identified to be Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffman La
                                     Roche, Mirna Therapeutics and Aphios Corporation. These key players showed immense activity in
                                     R&D in the early stages of drug development in different therapeutic areas like CNS,
                                     cardiovascular diseases, oncology, infection, immunological disorders and metabolic disorders.
                                     Hanall Pharmaceuticals has 39 molecules in discovery as well as preclinical stage Parkinson’s
                                     disease, diabetes, Alzheimer’s disease, hepatitis, allergy and hypertension. Patrys Limited has 19
                                     molecules in development in the discovery and preclinical stages of development in different
                                     therapeutic segments like ovarian cancer, lung cancer and colon cancer. Roche has 17 molecules
                                     in development in the discovery and preclinical stages of development in different therapeutic
                                     segments like prostate cancer, lung cancer, melanoma, breast cancer, colon cancer,
                                     schizophrenia, obesity and Human Immunodeficiency Virus (HIV) that causes Acquired
                                     Immunodeficiency Syndrome (AIDS).




Early Stage Drug Discovery in Disease Segments - Innovation                                              GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                      Page 3
                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                     1         Table of Contents
                                     1   Table of Contents ........................................................................................................................ 4
                                         1.1    List of Tables..................................................................................................................... 6
                                         1.2    List of Figures ................................................................................................................... 8
                                     2   Early Stage Drug Discovery in Disease Segments – Introduction ............................................. 10
                                         2.1    GBI Research Report Guidance ..................................................................................... 11
                                     3   Early Stage Drug Discovery in Disease Segments - Overview .................................................. 12
                                         3.1    Drug Discovery and Development .................................................................................. 12
                                            3.1.1    Drug Development-Stages ...................................................................................... 13
                                         3.2    Early Stage Drug Discovery Studies- An overview ......................................................... 15
                                         3.3    Early Stage Drug Discovery Design and Planning .......................................................... 16
                                            3.3.1    Early Stage Drug Discovery – Strategic Planning.................................................... 16
                                            3.3.2    Key Considerations During Early Stage Drug Discovery ......................................... 16
                                     4   Early Stage Drug Discovery in Disease Segments - Technology Landscape ............................ 18
                                         4.1    Current System ............................................................................................................... 18
                                            4.1.1    Overview ................................................................................................................. 18
                                            4.1.2    Key Technologies .................................................................................................... 18
                                            4.1.3    In-vitro ADMET Screening Models .......................................................................... 19
                                            4.1.4    In vivo ADMET Screening Models ........................................................................... 20
                                            4.1.5    In silico ADMET Screening models ......................................................................... 21
                                         4.2    Trends in Technology Models ......................................................................................... 22
                                            4.2.1    Recent Technology Developments .......................................................................... 22
                                     5   Early Stage Drug Discovery in Disease Segments - Drug Discovery and Development – A
                                         Challenge to Pharmaceutical Companies .................................................................................. 27
                                         5.1    Drug Discovery & Development Process ........................................................................ 27
                                            5.1.1    Drug Discovery Process .......................................................................................... 27
                                     6   Early Stage Drug Discovery in Therapeutic Segments .............................................................. 28
                                         6.1    Central Nervous System Disorders ................................................................................. 31
                                            6.1.1    Alzheimer’s disease ................................................................................................. 31
                                            6.1.2    Parkinson’s disease ................................................................................................. 37
                                            6.1.3    Multiple Sclerosis..................................................................................................... 42
                                            6.1.4    Schizophrenia .......................................................................................................... 47
                                         6.2    Metabolic Disorders ........................................................................................................ 52
                                            6.2.1    Diabetes .................................................................................................................. 52
                                            6.2.2    Obesity .................................................................................................................... 59
                                         6.3    Immunological Disorders ................................................................................................ 65
                                            6.3.1    Rheumatoid Arthritis ................................................................................................ 65
                                            6.3.2    Crohn’s Disease ...................................................................................................... 72
                                            6.3.3    Systemic Lupus Erythematosus (SLE) .................................................................... 77
                                            6.3.4    Allergy ..................................................................................................................... 82
                                         6.4    Infections......................................................................................................................... 87
                                            6.4.1    HIV/AIDS ................................................................................................................. 87
                                            6.4.2    Hepatitis A, B, C ...................................................................................................... 96
                                         6.5    Cardiovascular Diseases .............................................................................................. 104
                                            6.5.1    Hypertension ......................................................................................................... 104
                                            6.5.2    Dyslipidemia .......................................................................................................... 109
                                            6.5.3    Pulmonary Arterial Hypertension (PAH) ................................................................ 114
                                            6.5.4    Myocardial Infarction ............................................................................................. 119
                                         6.6    Oncology ....................................................................................................................... 124
                                            6.6.1    Bladder Cancer...................................................................................................... 124
                                            6.6.2    Lung Cancer .......................................................................................................... 129
                                            6.6.3    Non-Small Cell Lung Cancer (NSLC) .................................................................... 137
                                            6.6.4    Breast Cancer........................................................................................................ 143
                                            6.6.5    Colon Cancer......................................................................................................... 154


Early Stage Drug Discovery in Disease Segments - Innovation                                                                          GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                                                            Page 4
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                          6.6.6    Melanoma .............................................................................................................. 163
                                          6.6.7    Ovarian Cancer ..................................................................................................... 170
                                          6.6.8    Prostate Cancer..................................................................................................... 177
                                     7 Early Stage Drug Discovery in Disease Segments – Top Five Pharmaceutical Players in Early
                                       Stage Drug Discovery .............................................................................................................. 186
                                       7.1    Introduction ................................................................................................................... 186
                                       7.2    Hanall Pharmaceutical .................................................................................................. 187
                                          7.2.1    Company Overview ............................................................................................... 187
                                          7.2.2    Pipeline .................................................................................................................. 187
                                       7.3    Patrys Limited ............................................................................................................... 188
                                          7.3.1    Company Overview ............................................................................................... 188
                                          7.3.2    Pipeline .................................................................................................................. 189
                                       7.4    F. Hoffmann-La Roche Ltd. ........................................................................................... 189
                                          7.4.1    Company Overview ............................................................................................... 189
                                          7.4.2    Pipeline .................................................................................................................. 190
                                       7.5    Mirna Therapeutics ....................................................................................................... 190
                                          7.5.1    Company Overview ............................................................................................... 190
                                          7.5.2    Pipeline .................................................................................................................. 191
                                       7.6    Aphios Corporation ....................................................................................................... 191
                                          7.6.1    Company Overview ............................................................................................... 191
                                          7.6.2    Pipeline .................................................................................................................. 192
                                     8 Early Stage Drug Discovery in Disease Segments – Strategic Consolidations ....................... 193
                                       8.1    R&D Licensing Agreements .......................................................................................... 193
                                          8.1.1    Deals by Indication ................................................................................................ 193
                                          8.1.2    Deals by Geography .............................................................................................. 194
                                          8.1.3    Deal Summaries by Therapeutic Class ................................................................. 195
                                     9 Early Stage Drug Discovery in Disease Segments – Appendix ............................................... 202
                                       9.1    Market Definitions ......................................................................................................... 202
                                       9.2    Abbreviations ................................................................................................................ 202
                                       9.3    Research Methodology ................................................................................................. 207
                                          9.3.1    Coverage ............................................................................................................... 207
                                          9.3.2    Secondary Research ............................................................................................. 207
                                          9.3.3    Primary Research .................................................................................................. 208
                                          9.3.4    Expert Panel Validation ......................................................................................... 208
                                       9.4    Contact Us .................................................................................................................... 208
                                       9.5    Disclaimer ..................................................................................................................... 208
                                       9.6    Sources ......................................................................................................................... 209




Early Stage Drug Discovery in Disease Segments - Innovation                                                                        GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                                                         Page 5
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                     1.1     List of Tables

                                     Table 1:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Alzheimer’s Disease, December 2010 ............................................................ 32
                                     Table 2:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Parkinson’s Disease, December 2010 ............................................................ 38
                                     Table 3:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Multiple Sclerosis, December 2010 ................................................................. 44
                                     Table 4:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Schizophrenia, December 2010 ...................................................................... 49
                                     Table 5:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Diabetes, December 2010............................................................................... 54
                                     Table 6:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Obesity, December 2010................................................................................. 61
                                     Table 7:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Rheumatoid Arthritis Therapeutics, December 2010 ....................................... 67
                                     Table 8:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Crohn’s Disease, December 2010 .................................................................. 74
                                     Table 9:    Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in SLE, December 2010 ...................................................................................... 79
                                     Table 10:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Allergy, December 2010 .................................................................................. 84
                                     Table 11:   Early Stage Drug Discovery in Disease Segments, Global, Patent Expiries of Major
                                                 Marketed Drugs in HIV/AIDS, December 2010 .............................................................. 91
                                     Table 12:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in HIV/AIDS, December 2010 ............................................................................. 92
                                     Table 13:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Hepatitis Therapeutics, December 2010 ......................................................... 99
                                     Table 14:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Hypertension Therapeutics, December 2010 ................................................ 106
                                     Table 15:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Dyslipidemia Therapeutics, December 2010 ................................................. 111
                                     Table 16:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in PAH Therapeutics, December 2010 .............................................................. 117
                                     Table 17:   Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase
                                                 in PAH Therapeutics (%), December 2010 .................................................................. 117
                                     Table 18:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Myocardial Infarction Therapeutics, December 2010 .................................... 121
                                     Table 19:   Early Stage Drug Discovery in Disease Segments, Bladder Cancer Therapeutics,
                                                 Prevalence by Country, 2009 ....................................................................................... 124
                                     Table 20:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Bladder Cancer Therapeutics, December 2010 ............................................ 126
                                     Table 21:   Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase
                                                 in Bladder Cancer Therapeutics (%), December 2010 ................................................. 127
                                     Table 22:   Early Stage Drug Discovery in Disease Segments, Lung Cancer Categorized by Disease
                                                 Stage, December 2010 ................................................................................................ 129
                                     Table 23:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Lung Cancer Therapeutics, December 2010 ................................................. 133
                                     Table 24:   Early Stage Drug Discovery in Disease Segments, Global, NSCLC Treatment by Stage
                                                 of the Disease, December 2010 ................................................................................... 138
                                     Table 25:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in NSLC Therapeutics, December 2010 ........................................................... 140
                                     Table 26:   Early Stage Drug Discovery in Disease Segments, Breast Cancer Stage Classification,
                                                 December 2010............................................................................................................ 143
                                     Table 27:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Breast Cancer, December 2010 .................................................................... 148
                                     Table 28:   Early Stage Drug Discovery in Disease Segments, Global, Global, Staging of Colon
                                                 Cancer, December 2010 .............................................................................................. 155
                                     Table 29:   Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                                 Phase in Colon Cancer Therapeutics, December 2010 ............................................... 158
                                     Table 30:   Early Stage Drug Discovery in Disease Segments, Global, Staging of Melanoma,
                                                 December 2010............................................................................................................ 164

Early Stage Drug Discovery in Disease Segments - Innovation                                                                    GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                                                    Page 6
                                                                                   © GBI Research. This is a licensed product and is not to be photocopied
                                     Table 31: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                               Phase in Melanoma, December 2010 .......................................................................... 166
                                     Table 32: Early Stage Drug Discovery in Disease Segments, Global, Staging of Ovarian Cancer,
                                               December 2010............................................................................................................ 171
                                     Table 33: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                               Phase in Ovarian Cancer Therapeutics, December 2010 ............................................ 172
                                     Table 34: Early Stage Drug Discovery in Disease Segments, Global, Staging of Prostate Cancer,
                                               December 2010............................................................................................................ 177
                                     Table 35: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by
                                               Phase in Prostate Cancer Therapeutics, December 2010 ........................................... 179
                                     Table 36: Early Stage Drug Discovery in Disease Segments, Hanall Pharmaceutical – Pipeline
                                               Products, December 2010 ........................................................................................... 187
                                     Table 37: Early Stage Drug Discovery in Disease Segments, Patrys Limited – Pipeline Products,
                                               December 2010............................................................................................................ 189
                                     Table 38: Early Stage Drug Discovery in Disease Segments, F. Hoffmann-La Roche Ltd. –
                                               Pipeline Products, December 2010 .............................................................................. 190
                                     Table 39: Early Stage Drug Discovery in Disease Segments, Mirna Therapeutics, Inc. – Pipeline
                                               Products, December 2010 ........................................................................................... 191
                                     Table 40: Early Stage Drug Discovery in Disease Segments, Aphios Corporation, Inc. – Pipeline
                                               Products, December 2010 ........................................................................................... 192
                                     Table 41: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by
                                               Therapeutic Class, Metabolic Disorders (%), 2005–2010 ............................................ 195
                                     Table 42: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by
                                               Therapeutic Class, Immunological Disorders (%), 2005–2010 .................................... 196
                                     Table 43: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by
                                               Therapeutic Class, Cardiovascular Disorders (%), 2005–2010 .................................... 198
                                     Table 44: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by
                                               Therapeutic Class, Infections, 2005–2010 ................................................................... 199
                                     Table 45: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by
                                               Therapeutic Class, Oncology, 2005–2010 ................................................................... 200
                                     Table 46: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by
                                               Therapeutic Class, Central Nervous System Disorders, 2005–2010 ........................... 201




Early Stage Drug Discovery in Disease Segments - Innovation                                                                    GBIHC076MR / Published FEB 2011
Focuses on Stem Cell Therapies and Gene Therapies
                                                                                                                                                                   Page 7
                                                                                    © GBI Research. This is a licensed product and is not to be photocopied
                                     1.2      List of Figures
                                     Figure 1: Early Stage Drug Discovery in Disease Segments, Series of Research Activities Leading
                                                to Drug Discovery, December 2010 ............................................................................... 12
                                     Figure 2: Early Stage Drug Discovery in Disease Segments, Stages of Drug Development,
                                                December 2010.............................................................................................................. 15
                                     Figure 3: Early Stage Drug Discovery in Disease Segments, Preclinical ADMET Studies,
                                                December 2010............
								
To top
;